Page last updated: 2024-08-25

zoledronic acid and Lassitude

zoledronic acid has been researched along with Lassitude in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Conca, P; Di Minno, G; Matani, B; Rendina, D; Tufano, A1
Anderson, KC; Bianchi, G; Richardson, PG1
Archer, L; Burstein, HJ; Halabi, S; Hars, V; Hudis, C; Isaacs, C; Kirshner, J; Paskett, E; Schilsky, R; Shapiro, CL; Sikov, W; Weckstein, D; Winer, E1
Locke, FL; Morgan, GJ1
Decker, JL; Henderson, C; Hohneker, JA; Kaplan, BH; Lacerna, L; Orlowski, R; Purdy, MH; Schnell, FM; Vogel, CL; Wood, AJ; Yanagihara, RH1
Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, JG; Moukadem, WT; Nasr, FL; Yazbeck, NJ; Younes, FC1

Reviews

1 review(s) available for zoledronic acid and Lassitude

ArticleYear
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid

2012

Trials

3 trial(s) available for zoledronic acid and Lassitude

ArticleYear
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:5

    Topics: Adult; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Fatigue; Female; Fever; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Pain; Premenopause; Primary Ovarian Insufficiency; Prospective Studies; Zoledronic Acid

2011
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
    The oncologist, 2004, Volume: 9, Issue:6

    Topics: Aged; Arthralgia; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Creatinine; Diphosphonates; Fatigue; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Nausea; Pain; Pain Measurement; Prospective Studies; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid

2004
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
    Investigational new drugs, 2008, Volume: 26, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Zoledronic Acid

2008

Other Studies

2 other study(ies) available for zoledronic acid and Lassitude

ArticleYear
Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis.
    Internal and emergency medicine, 2019, Volume: 14, Issue:3

    Topics: Administration, Intravenous; Bone Density Conservation Agents; Fatigue; Humans; Hypocalcemia; Hypophosphatemia; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Zoledronic Acid

2019
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jul-10, Volume: 32, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid

2014